Noofambar 2021: Tijaabadii ugu horeysay ee caafimaad ee jiilka xiga ee kimeric antigen receptor T (CAR-T) daawaynta unug ee South Korea, kaas oo loogu talagalay in lagu hareer maro calaamadaha isbaarada difaaca, ayaa dhawaan bilowday.
Machadka Sare ee Sayniska iyo Tignoolajiyada ee Kuuriya (KAIST) ayaa ku dhawaaqay Arbacadii in tijaabada caafimaad ee Wajiga 1b ee daawaynta unugga CAR-T ay hadda ku socoto Xarunta Caafimaadka ee Samsung ee Seoul. Tijaabada waxa lagu samaynayaa 10 bukaan oo Kuuriyaan ah kuwaas oo soo laba kacleeyey oo kala firdhiyey lymphoma unugga weyn ee B. Xuquuqda suuq-geynta ee dhuumaha waxaa laga wareejiyay jaamacadda oo loo wareejiyay shirkadda Curocell, oo uu aasaasay Professor Kim Chan-hyuk. Curocell ayaa mas'uul ka ah barnaamijka horumarinta kiliinikada ee kacaanka immunotherapy.
In addition, a Phase 2 tijaabada caafimaadka involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for soo -dhoweeyaha kiimikada chimeric T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: CAR T-Cell therapy in Korea
Natiijooyinka daraasaddan ayaa lagu soo bandhigay maqaal lagu daabacay internetka ee arrinta Oktoobar ee Daaweynta Molecular.
